ATR Inhibitor with Radiation for Early HPV+ Throat Cancer
Part of Cancer, Infections clinical trials.
This study tests a new drug (ATRN-119) combined with targeted radiation therapy for people with early-stage HPV-positive throat cancer. The goal is to see if this combination helps shrink tumors and improves outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with early-stage (Stage I or II) HPV-positive throat cancer confirmed by biopsy
- Blood work shows healthy kidney, liver, and calcium levels
- No cancer spread to distant parts of the body
- No active infections or uncontrolled conditions like HIV, hepatitis, or high blood pressure
- Able to attend study visits and follow treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This trial tests a new combination of immunotherapy drugs and an HPV vaccine alongside chemotherapy and radiation for throat cancers caused by HPV. The goal is to see if this approach works as well as standard treatment while using less radiation, potentially reducing side effects.
This study tests whether patients with a specific type of HPV-positive throat cancer can safely skip radiation after surgery by using blood tests to monitor for cancer recurrence. The goal is to reduce side effects while keeping patients cancer-free.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.